NDA Filed for Idelalisib for Treating Non-Hodgkin Lymphoma Cancer Network The study included 125 patients with indolent non-Hodgkin lymphoma, and all patients were refractory to rituximab and to alkylating-agent-containing chemotherapy regimens. The analysis showed an overall response rate of 53.6%, and a median duration of ... |
